Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center.

Autor: Patil, Vijay M, Chandrasekharan, Arun, Vallathol, Dilip Harindran, Malhotra, Mridul, Abhinav, Ram, Agarwal, Priti, Rajpurohit, Anu, Tonse, Raees, Bhattacharjee, Atanu, Jalali, Rakesh
Předmět:
Zdroj: Neuro-Oncology Practice; Dec2019, Vol. 6 Issue 6, p479-483, 5p
Abstrakt: Background In our previous experience, a significant proportion of patients who received 5-HT3 antagonist monotherapy with adjuvant temozolomide (150-200 mg/m2) had chemotherapy-induced nausea and vomiting (CINV). This is an audit comparing the multiple antiemetic therapies in the prevention of temozolomide-associated CINV. Methods This was a retrospective audit. Adult glioma patients treated with temozolomide at a dose of 150-200 mg/m2 between October 2017 and June 2018 were selected for this analysis. Three antiemetic prophylaxis were used in this time period: ondansetron (October 2017 to November 2017), ondansetron + domperidone (December 2017 to February 2018), and ondansetron + olanzapine (March 2018 to June 2018). The rates of nausea and vomiting were compared among the 3 cohorts using the chi-squared test with Bonferroni correction. A P value of less than.016 was considered significant. Results A total of 360 patients were selected for this analysis. There were 91 patients in the ondansetron prophylaxis group (25.3%), 113 (31.4%) in the ondansetron plus domperidone group, and 156 (43.3%) in the ondansetron plus olanzapine group. The overall incidence of nausea and vomiting was 25.0% (n = 90) and 7.2% (n = 26). Overall the rates of nausea (P =.052) and vomiting (P =.481) were similar in all 3 cohorts. However, the rates of grade 2 and above nausea (P =.012) and vomiting (P =.015) were significantly lower in the olanzapine group. Conclusion The combination of ondansetron with olanzapine leads to a statistically significant decrease in the rate of moderate-to-severe emesis and nausea and needs to be explored in a prospective study. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje